SLC5A2 and chronic kidney disease: In this regard, Sano et al. [68] emphasize the beneficial effect of administering this SGLT2 inhibitor to diabetic patients with chronic kidney disease stages 2 and 3, with no beneficial effects observed in patients with severe renal impairment.